Smrithi Ravikumar

Afrihealth Optonet Association — Nigeria

Medicine · Health Sciences

5h-index52citations15works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(10), Biosimilars and Bioanalytical Methods(7), Immune Cell Function and Interaction(3), Autoimmune and Inflammatory Disorders Research(2), Immunodeficiency and Autoimmune Disorders(2)

Publications15 total

Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access
Blood·2025Open Access
Tali-cel is a safe and effective therapy in patients with Relapsed/Refractory B-cell non-Hodgkin lymphoma that allows equitable access- a real-world experience from India.
Blood·2025Open Access
A multicentre Phase I clinical trial demonstrates manufacturing feasibility, safety and activity of novel humanized BCMA-directed CAR-T cell therapy.
Blood·2025
POSTER: CT-1080 Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IECHS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
CT-1080: Incidence, Clinical Characteristics, and Risk Factors of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome (IEC-HS) in Patients Treated With Talicabtagene Autoleucel (Humanized Anti-CD19 CAR-T)
Clinical Lymphoma Myeloma & Leukemia·2025
Implementation of a CAR-T cell therapy program in India
Expert Review of Anticancer Therapy·2025· 4 cited
Talicabtagene autoleucel for relapsed or refractory B-cell malignancies: results from an open-label, multicentre, phase 1/2 study
The Lancet Haematology·2025· 8 cited
Talicabtagene Autoleucel (humanized CD19 CAR-T) As a Second Line Therapy in r/r B-Cell Lymphoma: Sub-Analysis from a Phase I/II Trial
Blood·2024· 2 citedOpen Access
Real World Data of Novel Talicabtagene Autoleucel (humanized CD19 CAR-T) from India; Ensuring Equitable Access with Excellent Safety and Efficacy Profile
Blood·2024· 5 cited
An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024
CT-643 An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
Clinical Lymphoma Myeloma & Leukemia·2024· 1 cited
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Blood·2023· 2 citedOpen Access
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Blood·2023· 12 cited
Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy
Blood·2022· 5 cited
Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
Blood·2022· 13 cited

Frequent Co-authors

Atharva Karulkar(15), Rahul Purwar(15), Devanshi Kalra(14), Shreshtha Shah(12), Afrin Firfiray(12), Lingaraj Nayak(12), Bhausaheb Bagal(12), Juber Pendhari(10), Manju Sengar(10), Hasmukh Jain(9), Alok Shetty(9), Nirali N. Shah(8), Ankesh Kumar Jaiswal(6), Gaurav Narula(6), Sattva S. Neelapu(6), Aalia Khan(5), Preeti Desai(5), Anisha Navkudkar(5), Anand Vaibhaw(5), Ashish Saroha(5)